INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA
- 1 November 2006
- journal article
- case report
- Published by Wolters Kluwer Health in Retina
- Vol. 26 (9), 1093-1094
- https://doi.org/10.1097/01.iae.0000254896.78766.74
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular DegenerationOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II TrialJournal of Clinical Oncology, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Bevacizumab suppresses choroidal neovascularisation caused by pathological myopiaBritish Journal of Ophthalmology, 2005
- Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopiaOphthalmology, 2003
- Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti–Vascular Endothelial Growth Factor Antibody FragmentArchives of Ophthalmology (1950), 2002